Diagnostyka i leczenie polipoidalnej waskulopatii naczyniówkowej

• Authors: Roksana Silicki , Marta Misiuk-Hojło

Title variants

EN

Diagnosis and management of polypoidal choroidal vasculopathy

• Languages of publication: PL

Abstracts

PL

Polipoidalną waskulopatię naczyniówkową uważa się za jeden z podtypów neowaskularnej formy zwyrodnienia plamki związanego z wiekiem, występujący szczególnie często u Azjatów. Choroba manifestuje się nawracającym surowiczo- -krwotocznym odwarstwieniem nabłonka barwnikowego siatkówki oraz polipoidalnymi, czerwonopomarańczowymi zmianami widocznymi w tylnym biegunie gałki ocznej. Przynależność polipoidalnej waskulopatii naczyniówkowej do spektrum zwyrodnienia plamki związanego w wiekiem budzi pewne kontrowersje ze względu na stosunkowo rzadkie występowanie w jej przypadku kilku charakterystycznych cech, takich jak: druzy, zmiany barwnikowe czy zanik RPE. Podczas wyboru optymalnej opcji terapeutycznej za każdym razem należy uwzględnić indywidualne cechy choroby pacjenta oraz dostępność narzędzi diagnostycznych i terapeutycznych.

EN

Polypoidal choroidal vasculopathy is considered to be one of the subtypes of the neovascular age-related macular degeneration, especially frequent in Asians. The disease is clinically manifested by the recurrent serosanguineous pigment epithelial detachment and polypoid reddish-orange nodules visible in the posterior segment of the globe. The association of polypoidal choroidal vasculopathy with the spectrum of age-related macular degeneration raises some controversies due to the relatively rare occurrence in its case of several characteristic findings such as drusen, pigment changes or RPE atrophy. Choosing the optimal therapeutic option for each patient the individual characteristics of the patient's disease and the availability of diagnostic and therapeutic tools should be considered.

Keywords

EN

angiografia indocyjaninowa; inhibitor naczyniowo-śródbłonkowego czynnika wzrostu naczyń; optyczna koherentna tomografia; polipoidalna waskulopatia naczyniówkowa; terapia fotodynamiczna; zwyrodnienie plamkizwiązane z wiekiem

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2018
• Volume: 5
• Issue: 4
• Pages: 228-234

Contributors

author

Roksana Silicki

• Katedra i Klinika Okulistyki, Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

author

Marta Misiuk-Hojło

• Katedra i Klinika Okulistyki, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

References

• 1. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008; 115: 116-126.
• 2. Ferris FL III, Fine SL, Hyman L. Age-related maculardegeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-1642.
• 3. Green WR, Enger C. Age-related macular degeneration histopathologic studies – the 1992 Zimmerman, Lorenz, E Lecture. Ophthalmology 1993; 100: 1519-1535.
• 4. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age‐related macular degeneration? Retina 2010; 30: 1333‐1349.
• 5. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10(1): 1-8.
• 6. Uyama M, Matsubara T, Fukushima I, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol 1999; 117: 1035-1042.
• 7. Imamura Y, Engelbert M, Iida T, et al. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 2010; 55(6): 501-515.
• 8. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol 2000; 238: 752-759.
• 9. Ma L, Li Z, Liu K, et al. Association of genetic variants with polypoidal choroidal vasculopathy: a systematic review and updated meta-analysis. Ophthalmology 2015; 122(9): 1854-1865.
• 10. Woo SJ, Ahn J, Morrison MA, et al. Analysis of genetic and environmental risk factors and their interactions in Korean patients with age-related macular degeneration. PLoS One 2015; 10(7): e0132771.
• 11. Kikuchi M, Nakamura M, Ishikawa K, et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology 2007; 114(9): 1722-1727.
• 12. Nakashizuka H, Mitsumata M, Okisaka S, et al. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 2008; 49(11): 4729-4737.
• 13. Okubo A, Sameshima M, Uemura A, et al. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol 2002; 86(10): 1093-1098.
• 14. Matsuoka M, Ogata N, Otsuji T, et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004; 88(6): 809-815.
• 15. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006; 141(3): 456-462.
• 16. Khan S, Engelbert M, Imamura Y, et al. Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye- -tracked spectral domain optical coherence tomography findings. Retina 2012; 32(6): 1057-1068.
• 17. Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011; 118(5): 840-845.
• 18. Dansingani KK, Balaratnasingam C, Naysan J, et al. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 2016; 36(3): 499-516.
• 19. Lee WK, Baek J, Dansingani KK, et al. Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina 2016; 36(suppl 1): S73-S82.
• 20. Koh AH, Expert PVC Panel, Chen LJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013; 33(4): 686-716.
• 21. Ozawa S, Ishikawa K, Ito Y, et al. Differences in macular morphology between polypoidal choroidal vasculopathy and exudative age-related macular degeneration detected by optical coherence tomography. Retina 2009; 29(6): 793-802.
• 22. Cackett P, Wong D, Yeo I. A classification system for poly-poidal choroidal vasculopathy. Retina 2009; 29(2): 187-191.
• 23. Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32(8): 1453-1464.
• 24. Kwok AK, Lai TY, Chan CW, et al. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol 2002; 86: 892‐897.
• 25. Byeon SH, Lew YJ, Lee SC, et al. Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy. Acta Ophthalmol 2010; 88(6): 660-668.
• 26. Lee JH, Lee WK. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters. Graefes Arch Clin Exp Ophthalmol 2016; 254(4): 645-651.
• 27. Kawamura A, Yuzawa M, Mori R, et al. Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol 2013; 91(6): 474-481.
• 28. Tan CS, Ngo WK, Lim LW, et al. A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes. Br J Ophthalmol 2014; 98(11): 1528-1533.
• 29. Cheung CM, Yanagi Y, Mohla A, et al. Characterization and differentiation of polypoidal choroidal vasculopathy using swept source optical coherence tomography angiography. Retina 2017; 37(8): 1464-1474.
• 30. Gemmy Cheung CM, Yeo I, Li X, et al. Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. Am J Ophthalmol 2013; 155(2): 295-304.
• 31. Wong CW, Cheung CM, Mathur R, et al. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review. Retina 2015; 35(8): 1577-1593.
• 32. Wakabayashi T, Gomi F, Sawa M, et al. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 2008; 92(7): 936-940.
• 33. Akaza E, Yuzawa M, Matsumoto Y, et al. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2007; 51(4): 270-277.
• 34. Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol 2017; 136(7): 786-793.
• 35. Koh A, Lai TYY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol 2017; 135(11): 1206-1213.

• Document Type: article